EP1534336A4 - Anticorps se fixant de facon immunospecifique a des recepteurs trail - Google Patents
Anticorps se fixant de facon immunospecifique a des recepteurs trailInfo
- Publication number
- EP1534336A4 EP1534336A4 EP03788476A EP03788476A EP1534336A4 EP 1534336 A4 EP1534336 A4 EP 1534336A4 EP 03788476 A EP03788476 A EP 03788476A EP 03788476 A EP03788476 A EP 03788476A EP 1534336 A4 EP1534336 A4 EP 1534336A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibodies
- immunospecifically bind
- trail receptors
- trail
- receptors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40338202P | 2002-08-15 | 2002-08-15 | |
US403382P | 2002-08-15 | ||
US42573002P | 2002-11-13 | 2002-11-13 | |
US425730P | 2002-11-13 | ||
US46805003P | 2003-05-06 | 2003-05-06 | |
US468050P | 2003-05-06 | ||
PCT/US2003/025457 WO2004016753A2 (fr) | 2002-08-15 | 2003-08-15 | Anticorps se fixant de facon immunospecifique a des recepteurs trail |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1534336A2 EP1534336A2 (fr) | 2005-06-01 |
EP1534336A4 true EP1534336A4 (fr) | 2005-12-14 |
Family
ID=31892094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03788476A Withdrawn EP1534336A4 (fr) | 2002-08-15 | 2003-08-15 | Anticorps se fixant de facon immunospecifique a des recepteurs trail |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1534336A4 (fr) |
AU (1) | AU2003259835A1 (fr) |
CA (1) | CA2494372C (fr) |
WO (1) | WO2004016753A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8288439B2 (en) * | 2003-11-04 | 2012-10-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for the inhibition of HIV-1 replication |
CA2546057A1 (fr) * | 2003-12-11 | 2005-06-23 | Schering Aktiengesellschaft | Procede permettant d'ameliorer l'efficacite de medicaments therapeutiques radiomarques |
US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
PE20090499A1 (es) | 2007-08-09 | 2009-05-18 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
AU2009223838B2 (en) | 2008-03-03 | 2012-07-26 | The University Of Miami | Allogeneic cancer cell-based immunotherapy |
US8992915B2 (en) | 2012-05-16 | 2015-03-31 | Boehringer Ingelheim International Gmbh | Combination of CD37 antibodies with ICE |
US20160067337A1 (en) | 2013-03-14 | 2016-03-10 | Bristol-Myers Squibb Company | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999037684A1 (fr) * | 1998-01-26 | 1999-07-29 | Genentech, Inc. | Anticorps du recepteur 4 de la mort cellulaire (dr4) et leurs utilisations |
WO2002009755A2 (fr) * | 2000-07-27 | 2002-02-07 | Genentech, Inc. | Synergisme de l'agoniste du recepteur de l'apo-2l et du cpt-11 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ529359A (en) * | 2001-05-25 | 2007-04-27 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to a TR4 polypeptide or polypeptide fragment or variant of TR4 and their use in a medicament for treating cancer |
-
2003
- 2003-08-15 EP EP03788476A patent/EP1534336A4/fr not_active Withdrawn
- 2003-08-15 CA CA2494372A patent/CA2494372C/fr not_active Expired - Lifetime
- 2003-08-15 AU AU2003259835A patent/AU2003259835A1/en not_active Abandoned
- 2003-08-15 WO PCT/US2003/025457 patent/WO2004016753A2/fr not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999037684A1 (fr) * | 1998-01-26 | 1999-07-29 | Genentech, Inc. | Anticorps du recepteur 4 de la mort cellulaire (dr4) et leurs utilisations |
WO2002009755A2 (fr) * | 2000-07-27 | 2002-02-07 | Genentech, Inc. | Synergisme de l'agoniste du recepteur de l'apo-2l et du cpt-11 |
Non-Patent Citations (10)
Title |
---|
CHUNTHARAPAI A ET AL: "Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 APR 2001, vol. 166, no. 8, 15 April 2001 (2001-04-15), pages 4891 - 4898, XP002336508, ISSN: 0022-1767 * |
DEJOSEZ M ET AL: "Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan", CELL DEATH AND DIFFERENTIATION, vol. 7, no. 11, November 2000 (2000-11-01), pages 1127 - 1136, XP002336507, ISSN: 1350-9047 * |
DILLMAN ROBERT O: "Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY. 15 AUG 2002, vol. 20, no. 16, 15 August 2002 (2002-08-15), pages 3545 - 3557, XP009050751, ISSN: 0732-183X * |
FULDA SIMONE ET AL: "Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo", NATURE MEDICINE, vol. 8, no. 8, August 2002 (2002-08-01), published online 15.07.2002, pages 808 - 815, XP002336506, ISSN: 1078-8956 * |
GLINIAK B ET AL: "Enhanced therapeutic efficacy of TRAIL/Apo2L in combination with CPT-11 in the treatment of human tumor xenografts", PROCEEDINGS OF THE 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. SAN FRANCISCO, CA, APRIL 1 - 5, 2000, PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, PHILADELPHIA, PA : AACR, US, vol. VOL. 41, 1 April 2000 (2000-04-01), pages 70, XP002207071 * |
GLINIAK B ET AL: "TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND'S ANTITUMORACITVITY IN VIVO IS ENHANCED BY THE CHEMOTHERAPEUTIC AGENT CPT-11", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 24, 15 December 1999 (1999-12-15), pages 6153 - 6158, XP000941885, ISSN: 0008-5472 * |
INOUE H ET AL: "HISTONE DEACETYLASE INHIBITORS SENSITIZE HUMAN COLONIC ADENOCARCINOMA CELL LINES TO TNF-RELATED APOPTOSIS INDUCING LIGAND-MEDIATED APOPTOSIS", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, SPANDIDOS, ATHENS, GR, vol. 9, no. 5, May 2002 (2002-05-01), pages 521 - 525, XP009007225, ISSN: 1107-3756 * |
MITSIADES CONSTANTINE S ET AL: "TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: Therapeutic applications", BLOOD, vol. 98, no. 3, 1 August 2001 (2001-08-01), pages 795 - 804, XP002336504, ISSN: 0006-4971 * |
NIMMANAPALLI R ET AL: "Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. FEB 2001, vol. 7, no. 2, February 2001 (2001-02-01), pages 350 - 357, XP002336505, ISSN: 1078-0432 * |
ROEHN TILL A ET AL: "CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release", ONCOGENE, vol. 20, no. 31, 12 July 2001 (2001-07-12), pages 4128 - 4137, XP002336509, ISSN: 0950-9232 * |
Also Published As
Publication number | Publication date |
---|---|
WO2004016753A2 (fr) | 2004-02-26 |
AU2003259835A8 (en) | 2004-03-03 |
CA2494372A1 (fr) | 2004-02-26 |
EP1534336A2 (fr) | 2005-06-01 |
AU2003259835A1 (en) | 2004-03-03 |
WO2004016753A3 (fr) | 2004-06-17 |
CA2494372C (fr) | 2013-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1465925A4 (fr) | Anticorps se liant de maniere immunospecifique a des recepteurs trail | |
HK1075470A1 (en) | Antibodies that immunospecifically bind to trail receptors | |
EP1572874A3 (fr) | Anticorps se liant de maniere immunospecifique a des recepteurs de trail | |
TWI366570B (en) | Antibodies to madcam | |
AU2002364954A8 (en) | Antibodies that immunospecifically bind to blys | |
EP1411983A4 (fr) | Anticorps bispecifiques se liant aux recepteurs vegf | |
GB0417384D0 (en) | Antibodies to c-met | |
CY2012003I1 (el) | Αντισωματα που συνδεονται ανοσοειδικως προς blys | |
EP1535930A4 (fr) | Anticorps specifique a une proteine-tetra centrale | |
HK1178921A1 (en) | Antibodies to m-csf m-csf | |
AU2003295411A8 (en) | Human monoclonal antibodies to heparanase | |
IL173965A0 (en) | Peptides and compounds that bind to thrombopoietin receptors | |
AU2003234706A8 (en) | Antibodies that specifically bind to tl5 | |
AU2003218456A8 (en) | Antibodies that specifically bind to gmad | |
EP1633316A4 (fr) | Anticorps se liant de maniere immunospecifique aux recepteurs trail | |
AU2003240822A8 (en) | Antibodies that specifically bind to neurokinin b | |
AU2003256299A8 (en) | Antibodies that specifically bind to reg iv | |
AU2003259835A8 (en) | Antibodies that immunospecifically bind to trail receptors | |
EP1339426A4 (fr) | Anticorps a liaison immunospecifique avec les recepteurs "trail" | |
AU2002352676A1 (en) | Antibodies that immunospecifically bind to trail receptors | |
AU2002368062A1 (en) | Bispecific antibodies that bind to vegf receptors | |
AU2003228483A8 (en) | Antibodies that specifically bind to tr2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050314 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7C 07K 16/28 B Ipc: 7C 07K 16/00 B Ipc: 7A 61K 39/395 A |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20051028 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20061020 |